The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
This content was published on
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
Dangerous delivery: how doctors in Geneva handled the hantavirus
This content was published on
Geneva University Hospital was the first to identify the hantavirus variant behind an outbreak on a cruise ship in May 2026. Here’s how it did it.
When sperm crosses borders, national safeguards fall short
This content was published on
The sperm of a Danish donor carried a cancer-causing genetic mutation that led to the deaths of children. Switzerland’s strict regulations make scenarios of this scale unlikely.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
Swiss regulator and media clash over weight-loss drugs
This content was published on
Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.
Medicines regulators weigh hope and hype with new Alzheimer’s drugs
This content was published on
Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision won’t be easy.
From Covid to Hormuz, what has Switzerland learned about drug shortages?
This content was published on
While immediate drug shortages aren’t expected, experts say the Middle East conflict could impact medicine availability in Switzerland.
Explainer: why Roche’s supercomputer is a big deal
This content was published on
Pharma companies are racing to acquire microchips and achieve the most powerful AI capacity in the industry. But drug development is tricky and AI talents scarce.
Why unemployment in Switzerland is increasing more than elsewhere in Europe
This content was published on
The number of people in Switzerland who are out of work increased for the second year in a row. This contrasts with the situation in the European Union.
US trade deal forces reckoning for Swiss pharma powerhouse
This content was published on
Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry’s future in Switzerland.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
This content was published on
Ypsomed CEO explains why US tariffs are not a worry and why he sees more growth from diabetes and obesity treatments such as Ozempic.
Dangerous delivery: how doctors in Geneva handled the hantavirus
This content was published on
Geneva University Hospital was the first to identify the hantavirus variant behind an outbreak on a cruise ship in May 2026. Here’s how it did it.
From Covid to Hormuz, what has Switzerland learned about drug shortages?
This content was published on
While immediate drug shortages aren’t expected, experts say the Middle East conflict could impact medicine availability in Switzerland.
How Switzerland bought rapid access to Covid vaccines
This content was published on
Switzerland released full Covid vaccine contracts, revealing the prices and terms it took for rapid access to vaccines during the pandemic.
Cured but uninsurable: the hidden financial burden of surviving cancer in Switzerland
This content was published on
More people are surviving cancer than ever before. But in Switzerland a historical diagnosis can follow former patients for years.
Can Swiss pharma giant Roche reshape the obesity market?
This content was published on
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive market.
The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
When sperm crosses borders, national safeguards fall short
This content was published on
The sperm of a Danish donor carried a cancer-causing genetic mutation that led to the deaths of children. Switzerland’s strict regulations make scenarios of this scale unlikely.
How Switzerland became liberal on abortion – without noticing
This content was published on
From 2027 Swiss health insurers will cover the full cost of abortions. The change passed through parliament almost unnoticed.
Crans-Montana: when a medical bill is not just a bill
This content was published on
After the deadly bar fire in Crans-Montana, unexpected hospital invoices sent across the border ignited tensions between Switzerland and Italy – and revealed how systems clash when tragedy strikes.
Dangerous delivery: how doctors in Geneva handled the hantavirus
This content was published on
Geneva University Hospital was the first to identify the hantavirus variant behind an outbreak on a cruise ship in May 2026. Here’s how it did it.
Good news for Switzerland: US is fast-tracking psychedelics for mental health
This content was published on
Switzerland is the only country in Europe offering psychedelic treatments, but access remains extremely limited for patients. US support means things could change. An analysis by Swissinfo.
Truth or tale: can pharma companies set prices for new drugs as high as they want?
This content was published on
Debates over drug pricing have prompted Swissinfo readers to ask whether pharma companies can set prices for new drugs as high as they want.
From Covid to Hormuz, what has Switzerland learned about drug shortages?
This content was published on
While immediate drug shortages aren’t expected, experts say the Middle East conflict could impact medicine availability in Switzerland.
How Switzerland bought rapid access to Covid vaccines
This content was published on
Switzerland released full Covid vaccine contracts, revealing the prices and terms it took for rapid access to vaccines during the pandemic.
Cured but uninsurable: the hidden financial burden of surviving cancer in Switzerland
This content was published on
More people are surviving cancer than ever before. But in Switzerland a historical diagnosis can follow former patients for years.
Can Swiss pharma giant Roche reshape the obesity market?
This content was published on
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive market.
Explainer: why Roche’s supercomputer is a big deal
This content was published on
Pharma companies are racing to acquire microchips and achieve the most powerful AI capacity in the industry. But drug development is tricky and AI talents scarce.
Trump promised the ‘world’s lowest’ drug prices. We checked the numbers.
This content was published on
The TrumpRx website claims to offer the best prices for medications. Here’s where Americans still pay more — and much more.
Drugmakers reassess Europe as Trump overhauls drug-pricing rules
This content was published on
President Trump’s drug-pricing overhaul has triggered an earthquake in Europe as drugmakers scramble to protect their bottom lines.
Why unemployment in Switzerland is increasing more than elsewhere in Europe
This content was published on
The number of people in Switzerland who are out of work increased for the second year in a row. This contrasts with the situation in the European Union.
The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
Could a Danish‑style sperm donor scandal happen in Switzerland?
This content was published on
A sperm donor in Denmark carrying a cancer‑causing gene had almost 200 children… Could something like that happen in Switzerland?
This content was published on
In episode 6 of this season’s Swiss Connection science podcast, we look at the role of relationships and perceptions in longevity.
When sperm crosses borders, national safeguards fall short
This content was published on
The sperm of a Danish donor carried a cancer-causing genetic mutation that led to the deaths of children. Switzerland’s strict regulations make scenarios of this scale unlikely.
Science podcast: the story behind the ‘longevity pill’ rapamycin
This content was published on
In episode 5 of this season’s Swiss Connection science podcast, we talk about the discovery of TOR and its potential for longevity.
This content was published on
Medical experts now use artificial intelligence to help them diagnose and monitor diseases. But does this mean AI will replace doctors?
From London to Lausanne: how Isomorphic Labs is rewriting drug discovery
This content was published on
Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to “solve all diseases” with AI.
Science podcast: Can gender diversity create better medicine?
This content was published on
In episode 3 of this season’s Swiss Connection science podcast we look at the role of sex and gender in drug development.
